Levi & Korsinsky has launched a securities investigation into Altria Group following a sharp stock decline on July 30, 2026, after the company reported second-quarter results that missed Wall Street consensus on both earnings and revenue and lowered its full-year outlook. The investigation focuses on whether Altria adequately disclosed regulatory and financial risks tied to statements made on its April 30, 2026 earnings call, where CFO Sal Mancuso reaffirmed a 2026 full-year adjusted diluted EPS range of $5.56 to $5.72 and CEO Billy Gifford described on! PLUS as the first and only product authorized under the FDA's pilot program while stating that the science behind additional pending applications provides a basis for FDA authorization within the 180-day statutory timeline. Shareholders who suffered losses on their Altria investment are encouraged to contact the firm for a free case evaluation.
Altria GroupQ2 results missed consensus and full-year outlook lowered, triggering investigation into disclosures.
